Phase 1 N=41 Chewing Gum Use to Reduce Post-operative Ileus in Pediatric Patients
Post Operative Ileus
Primary: Post-Operative Hospital Stay — 79.93; 72.94 hours — p=0.665
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis
Allergic Rhinitis
Primary: Cmax (the Maximum Observed Plasma Concentration) — 1630.223; 1729.393; 1617.810 ng/mL
Phase 1 N=23 Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
Lymphoma · Small Intestine Cancer
Primary: Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation — 12; 11; 11; 10 patients
Phase 1 N=58 Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers
Healthy
Primary: AUC0-168 (Area Under the Concentration-time Curve of Clonidine in Plasma Over the Time Interval From 0 to 168 h) — 82517.99; 80641.47 pg*h/mL — p=<0.0001
Phase 1 N=32 A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
Pulmonary Disease, Chronic Obstructive
Primary: Cmax,ss (Olodaterol) — 4.33; 2.82 picogram/milliliter (pg/mL)
Phase 1 N=33 Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Clinical Response as Assessed Metabolically by Changes in Positron Emission Tomography (PET) Scan Between Baseline and Immediately Prior to Surgery. — 78; 64; 50; 22…
Phase 1 N=24 Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers
Malaria
Primary: Individual Parasite Reduction Ratio (PRR) — 1132; 217646; 314040; 8021 none (ratio)
Phase 1 N=26 Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations
Acute Pain
Primary: Cmax — 3290.70; 2785.90 ng/mL
Phase 1 N=52 Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis
Ulcerative Colitis
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State — 21411; 46173; 49213 ug*h/L
Phase 1 N=26 Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant
Hypertension
Primary: Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC) — 298; 640; 702 ng*h/mL
Phase 1 N=9 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Tolerated Dose — 80 mg/m^2
Phase 1 N=52 A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Solid Cancers
Primary: Geometric Mean Ratio of the Area Under the Plasma Concentration-time Curve From 0 to Infinity (AUC[0-inf]) of Rosiglitazone — 92.0 ng/mL*hr
Phase 1 N=28 A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 36.256; 38.198…
Phase 1 N=24 A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)
Heartburn
Primary: Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Famotidine/Antacid Combination EZ Chew Without Water and Famotidine/Antacid Tablet With…
Phase 1 N=14 Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology
Hypoplastic Left Heart Syndrome · Single Ventricle · Heart Failure
Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants